Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Genasense Injection for multiple myeloma trial did not reach primary end-point
December 28th, 2004
Genta Incorporated (NASDAQ:GNTA) announced that the company's randomized phase 3 clinical trial of Genasense (oblimersen sodium) Injection in patients with advanced multiple myeloma did not meet its primary end-point. The trial had been designed to evaluate whether the addition of Genasense to standard therapy with high-dose dexamethasone could increase the time to development of progressive disease in patients who previously had received extensive therapy. "The strength of the preclinical data, combined with results from two preliminary, nonrandomized trials, provided a strong rationale for this phase 3 study," said Dr. Raymond P. Warrell, Jr.,...
Source: Cancer Weekly (2004-12-28)
|
